Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 685

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis

Open access
Adachi, Jonathan D., Bensen, William G., Brown, Jacques, Hanley, David, Hodsman, Anthony, Josse, Robert, Kendler, David L., Lentle, Brian, Olszynski, Wojciech, Ste.-Marie, Louis-George, Tenenhouse, Alan, Chines, Arkadi A., Jovaisas, Algis, Sturtridge, William C., Anastassiades, Tassos P., Hanly, John G., Pope, Janet E., Dias, Reginald, Horowitz, Zebulun D., Pack, Simon·1997·New England Journal of Medicine

Abstract

BACKGROUND AND METHODS: Osteoporosis is a recognized complication of corticosteroid therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized, placebo-controlled study of intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles, in 141 men and women (age, 19 to 87 years) who had recently begun high-dose corticosteroid therapy. The primary outcome measure was the difference in the change in the bone density of the lumbar spine between the groups from base line to week 52. Secondary measures included changes in the bone density of the femoral neck, trochanter, and radius and the rate of new vertebral fractures. RESULTS: The mean (+/-SE) bone density of the lumbar spine and trochanter in the etidronate group increased 0.61 +/- 0.54 and 1.46 +/- 0.67 percent, respectively, as compared with decreases of 3.23 +/- 0.60 and 2.74 +/- 0.66 percent, respectively, in the placebo group. The mean differences between the groups after one year were 3.72 +/- 0.88 percentage points for the lumbar spine (P = 0.02) and 4.14 +/- 0.94 percentage points for the trochanter (P = 0.02). The changes in the femoral neck and the radius were not significantly different between the groups. There was an 85 percent reduction in the proportion of postmenopausal woman with new vertebral fractures in the etidronate group as compared with the placebo group (1 of 31 patients vs. 7 of 32 patients, P = 0.05), and the etidronate-treated postmenopausal women also had significantly fewer vertebral fractures per patient (P = 0.04). CONCLUSIONS: Intermittent etidronate therapy prevents the loss of vertebral and trochanteric bone in corticosteroid-treated patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199708073370603

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 685

Metadata

Authors
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., Tenenhouse, A., Chines, A. A., Jovaisas, A., Sturtridge, W. C., Anastassiades, T. P., Hanly, J. G., Pope, J. E., Dias, R., Horowitz, Z. D., & Pack, S.
Venue
New England Journal of Medicine
Published
1997-08-07
Volume
337
Issue
6
Pages
382-388
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2335475908
Cited by
685
References
13
FWCI
67.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis. https://app.cochat.ai/papers/10.1056/nejm199708073370603
The paper
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., Tenenhouse, A., Chines, A. A., Jovaisas, A., Sturtridge, W. C., Anastassiades, T. P., Hanly, J. G., Pope, J. E., Dias, R., Horowitz, Z. D., & Pack, S. (1997). Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis. New England Journal of Medicine. https://doi.org/10.1056/nejm199708073370603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.